Combining Food Biodiversity, Less Processing, and the EAT‑Lancet Diet Improves Nutrient Adequacy and Lowers Environmental Impact: Insights from 368,733 EPIC Participants

Combining Food Biodiversity, Less Processing, and the EAT‑Lancet Diet Improves Nutrient Adequacy and Lowers Environmental Impact: Insights from 368,733 EPIC Participants

Multi-objective optimization in the EPIC cohort shows that modest gains in adherence to the EAT‑Lancet diet, increased plant species richness, and substitution of ultra‑processed foods with minimally processed foods can raise nutrient adequacy and reduce greenhouse gas emissions and land use.
Rigid Gas-Permeable Contact Lenses Improve Visual Rehabilitation After Primary Congenital Glaucoma Surgery: Results of the CLEVR‑PCG Randomized Trial

Rigid Gas-Permeable Contact Lenses Improve Visual Rehabilitation After Primary Congenital Glaucoma Surgery: Results of the CLEVR‑PCG Randomized Trial

In children after primary congenital glaucoma surgery with poor spectacle response, rigid gas‑permeable contact lenses produced greater improvements in worse‑eye visual acuity, contrast sensitivity, and near stereoacuity over 12 months compared with continued spectacle wear.
Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit

Routine 5–7 Day Antibiotic Prophylaxis After Upper GI Bleeding in Cirrhosis: New Meta-analysis Questions the Mortality Benefit

A 2025 bayesian meta-analysis of 14 RCTs (n=1,322) found shorter or no antibiotic prophylaxis after upper GI bleeding in cirrhosis was highly likely to be noninferior for mortality, though it increased reported bacterial infections. Study limitations temper definitive practice change.
Guideline‑Level Moderate–Vigorous Physical Activity Appears Safe and Beneficial for Phenotype‑Negative Car cardiomyopathy Variant Carriers

Guideline‑Level Moderate–Vigorous Physical Activity Appears Safe and Beneficial for Phenotype‑Negative Car cardiomyopathy Variant Carriers

In a large UK Biobank cohort, accelerometer-measured moderate‑to‑vigorous physical activity (100–400 min/week) was associated with lower cardiovascular risk and no excess arrhythmic or cardiomyopathy onset among genotype‑positive phenotype‑negative (G+P-) cardiomyopathy variant carriers.
International Reference Values for Total Pancreatectomy Show Higher Perioperative Risk Than Pancreatoduodenectomy — Practical Benchmarks for Quality Control

International Reference Values for Total Pancreatectomy Show Higher Perioperative Risk Than Pancreatoduodenectomy — Practical Benchmarks for Quality Control

This multicenter study defines international perioperative reference values for total pancreatectomy (TP). Even low‑risk TP carries higher morbidity and mortality than pancreatoduodenectomy; outcomes worsen with vascular resection or conversion for high‑risk anastomosis.
Thyroid Cancer in Adolescents and Young Adults Is Surging Worldwide — But Deaths Aren’t: Strong Evidence of Overdiagnosis from a 185‑Country Analysis

Thyroid Cancer in Adolescents and Young Adults Is Surging Worldwide — But Deaths Aren’t: Strong Evidence of Overdiagnosis from a 185‑Country Analysis

A 185-country study shows large, sustained increases in thyroid cancer incidence among adolescents and young adults (15–39 years) since the 2000s while mortality remains low and stable — a pattern most consistent with widespread overdiagnosis and overtreatment.
High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets

High, Persistent Breast Cancer Mortality in Sub‑Saharan Africa: 7‑Year ABC‑DO Cohort Reveals Major Survival Gaps and Actionable Targets

A 7‑year follow-up of 2,153 women in the ABC‑DO cohort shows poor breast cancer survival in much of sub‑Saharan Africa, with 5‑year crude survival 40% and marked between-country and racial disparities; reaching WHO stage downstaging targets and improving treatment access could cut deaths by about a third.
Fixed‑Duration Venetoclax After RBAC Improves 2‑Year PFS in High‑Risk Older Mantle Cell Lymphoma: Final Results of the FIL_V‑RBAC Phase 2 Study

Fixed‑Duration Venetoclax After RBAC Improves 2‑Year PFS in High‑Risk Older Mantle Cell Lymphoma: Final Results of the FIL_V‑RBAC Phase 2 Study

In a multicentre, risk‑adapted phase 2 trial, adding fixed‑duration venetoclax after rituximab‑bendamustine‑cytarabine (RBAC) produced a 2‑year progression‑free survival of 60% in older patients with high‑risk mantle cell lymphoma (MCL). Toxicities were manageable, neutropenia was most common, and one treatment‑related death occurred.